Neo Ivy Capital Management - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 322 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
Neo Ivy Capital Management ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2023$207
-100.0%
5,602
-69.7%
0.46%
-18.6%
Q3 2021$496,000
+740.7%
18,496
+1332.7%
0.57%
+848.3%
Q2 2021$59,000
-52.4%
1,291
-56.5%
0.06%
-55.9%
Q1 2021$124,000
-63.5%
2,966
-62.7%
0.14%
-64.1%
Q4 2020$340,000
+45.9%
7,952
-10.6%
0.38%
+60.6%
Q3 2020$233,000
-88.0%
8,895
-91.3%
0.24%
-67.8%
Q2 2020$1,939,000
+6586.2%
102,462
+6336.1%
0.73%
+1459.6%
Q1 2020$29,000
-92.4%
1,592
-93.1%
0.05%
-81.1%
Q3 2019$381,000
-73.6%
23,093
-72.5%
0.25%
-69.4%
Q2 2019$1,443,00083,9660.81%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Third Security, LLC 19,816,162$195,784,0009.33%
BB BIOTECH AG 5,846,564$57,764,0002.74%
QVT Financial LP 4,556,090$45,014,0002.44%
Parametrica Management Ltd 29,578$292,0002.21%
SECTORAL ASSET MANAGEMENT INC 4,389,682$43,370,0001.84%
Belmont Global Advisors, Inc. 257,000$2,539,0001.83%
HARVEY CAPITAL MANAGEMENT INC 394,550$3,898,0001.40%
Lombard Odier Asset Management (USA) Corp 1,350,000$13,338,0000.70%
IRIDIAN ASSET MANAGEMENT LLC/CT 6,199,685$61,253,0000.63%
Callan Capital, LLC 199,230$1,968,0000.53%
View complete list of HALOZYME THERAPEUTICS INC shareholders